Skip to main content

Table 1 Baseline demographics, characteristics, and GH treatment duration

From: Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program

Characteristic

Overall

GHD

ISS

TS

 

(N = 261)

(n = 201)

(n = 19)

(n = 41)

 

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

Sex, M/F

173/88

 

158/43

 

15/4

 

0/41

 

Chronologic age (CA), y

        

   All NAH criteria

261

14.0 ± 2.1

201

14.2 ± 1.9

19

14.0 ± 1.9

41

13.1 ± 2.5

   age >18 y

178

14.9 ± 1.5

149

14.9 ± 1.5

13

14.6 ± 1.4

16

14.9 ± 2.2

   male, age >16 y,

20

12.7 ± 1.9

18

12.5 ± 1.9

2

14.6 ± 0.06

-

-

   HV < 2 cm/y

        

   female, age >15 y, HV <2 cm/y

63

12.2 ± 2.1

34

12.4 ± 2.1

4

11.9 ± 2.3

25

11.9 ± 2.0

Bone age (BA), y

215

11.7 ± 2.0

169

11.9 ± 1.9

16

11.6 ± 2.2

30

11.0 ± 2.2

BA/CA ratio

215

0.85 ± 0.08

169

0.85 ± 0.08

16

0.84 ± 0.08

30

0.84 ± 0.09

HSDS

        

   All NAH criteria

261

-2.8 ± 0.6

201

-2.7 ± 0.5

19

-2.8 ± 0.6

41

-3.0 ± 0.6

   age >18 y

178

-2.8 ± 0.6

149

-2.7 ± 0.6

13

-2.9 ± 0.7

16

-2.9 ± 0.7

   male, age >16 y, HV < 2 cm/y

20

-2.5 ± 0.4

18

-2.5 ± 0.4

2

-2.6 ± 0.0

-

-

   female, age >15 y, HV <2 cm/y

63

-2.8 ± 0.5

34

-2.7 ± 0.5

4

-2.6 ± 0.3

25

-3.0 ± 0.6

Target HSDS

222

-0.3 ± 0.8

171

-0.3 ± 0.8

18

-0.7 ± 0.7

33

0.2 ± 0.9

Corrected HSDS

221

-2.1 ± 4.1

169

-2.1 ± 4.0

18

-2.1 ± 0.7

34

-1.8 ± 5.3

Predicted HSDS*

186

-1.4 ± 1.1

143

-1.2 ± 1.0

13

-1.6 ± 1.1

30

-2.1 ± 0.9

IGF-I SDS

187

-2.6 ± 1.60

152

-2.7 ± 1.60

12

-2.3 ± 1.81

23

-1.7 ± 1.22

BMI, kg/m2

260

19.9 ± 4.5

201

19.7 ± 4.5

18

18.1 ± 2.8

41

21.4 ± 4.9

BMI SDS

260

-0.21 ± 1.38

201

-0.32 ± 1.44

18

-0.68 ± 1.05

41

0.53 ± 0.90

Peak GH, ng/mL

166

6.9 ± 5.7

148

5.5 ± 2.8

14

20.3 ± 9.7

4

10.9 ± 8.7

Initial GH dose, mg/kg/d

259

0.048 ± 0.012

199

0.047 ± 0.013

19

0.050 ± 0.006

41

0.052 ± 0.008

Treatment duration, y

261

4.0 ± 1.6

201

3.9 ± 1.5

19

3.9 ± 1.5

41

4.4 ± 2.0

  1. Abbreviations: BMI body mass index, GH growth hormone, GHD growth hormone deficiency, HSDS height standard deviation score, IGF-I insulin-like growth factor-1, ISS idiopathic short stature, M/F male/female, TS Turner syndrome, SDS standard deviation score; y, years.
  2. Predicted HSDS was calculated by the Bayley-Pinneau method [17] using a child’s current height, sex, chronological age, and bone age.